Hepatitis

This study tested giving hepatitis C treatment to people who inject drugs while they were already in the hospital for other infections. The goal was to cure their hepatitis C and make sure they stayed connected to care afterward. The study was stopped early, but it included 21 pa…

This study tested a drug called INT-787 in 67 people with severe alcohol-associated hepatitis, a serious liver condition. The trial was a phase 2a proof-of-concept study, but it was terminated early. Researchers were looking at safety, how well the drug works, and how the body pr…

This study tested two antiviral drugs, clevudine and tenofovir, alone or together, in 150 adults with chronic hepatitis B who had not been treated before. The goal was to see which approach worked best at controlling the virus after 96 weeks of treatment and 24 weeks of follow-up…

This study tested whether a new drug called ARC-520, given with the standard medicine entecavir, could lower hepatitis B virus levels in people with chronic hepatitis B. About 58 adults with different stages of infection received either ARC-520 or a placebo. The study was stopped…

This small, early-phase study tested whether the heart medication digoxin could reduce inflammation in people with severe alcohol-associated hepatitis. 23 participants were randomly assigned to receive intravenous digoxin or no digoxin for up to 28 days. The trial was terminated …

This study looked at whether tiny bits of RNA in the blood can serve as markers for liver disease and liver cancer. Researchers collected blood samples from nearly 1,900 people with liver cancer, cirrhosis, or chronic liver disease. The goal was to see if these RNA markers could …

This study observed over 1,700 adults with chronic hepatitis B in the US and Canada to understand how the disease progresses and how treatments are used in everyday medical practice. Researchers collected data from both academic and community clinics to build a real-world picture…

This early-phase study looked at whether giving vitamin A along with the pneumococcus vaccine (Prevnar) helps children ages 1 to 4 build a stronger immune response. Only 22 healthy kids were enrolled before the study was stopped early. Researchers measured antibody levels in the …